Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06112340 · ClinicalTrials.gov registry record · Phase 2
Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
A Phase 2 study of Eye Diseases and Thyroid Eye Disease, sponsored by Sling Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 75
- Enrollment target
- 2
- Study locations
NCT06112340: Recruiting Phase 2 study of Eye Diseases and Thyroid Eye Disease, sponsored by Sling Therapeutics.
NCT06112340 is a Phase 2 study of Eye Diseases and Thyroid Eye Disease that is actively recruiting participants, run by Sling Therapeutics. The registered enrollment target is 75 participants, below the 741,300-participant average among 27 other Eye Diseases trials with a reported enrollment target (100% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06112340, a Phase 2 study of Eye Diseases and Thyroid Eye Disease, is actively recruiting participants, sponsored by Sling Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 75 participants
- Enrollment target
- 2
- Study locations
Study Summary
The overall study objective is to continue to assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of linsitinib in subjects who were enrolled in the prior VGN-TED-301 through Week 24. These subjects include VGN-TED-301 Week 24 proptosis non-responders or subjects who relapse during the Follow-Up Period of VGN-TED-301.
Primary Outcome
Percentage of subjects with a ≥ 2 mm reduction of proptosis from baseline as determined by exophthalmometer
Conditions Studied
Interventions
- DRUG linsitinib
Study Locations (2)
Florida
- Bascom Palmer Eye Institute - Miami
West Virginia
- West Virginia University Eye Institute - Morgantown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2023-10-11 |
| Est. Completion | 2026-06 |
| Phase | Phase 2 |
What NCT06112340 shows while recruiting
NCT06112340 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 75 participants, a relatively small participant target, below the 741,300-participant average among 27 other Eye Diseases trials with a reported enrollment target (100% lower).
The record links to 10 conditions, with Eye Diseases appearing as the primary indexed condition, and to 1 intervention - of which linsitinib is the first listed.
NCT06112340 reports a single indexed study location in Florida, West Virginia.
Frequently Asked Questions
What is clinical trial NCT06112340 about?
NCT06112340 is a clinical study titled "Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)". The overall study objective is to continue to assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of linsitinib in subjects who were enrolled in the prior VGN-TED-301 through Week 24. These subjects include VGN-TED-301 Week 24 proptosis non-responders or subjects who relapse during t...
What is the current status of trial NCT06112340?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 75 participants. The study started on 2023-10-11. Estimated completion is 2026-06.
What conditions does trial NCT06112340 study?
This clinical trial studies the following conditions: Eye Diseases, Thyroid Eye Disease, Endocrine System Diseases, Graves Ophthalmopathy, Thyroid Diseases.
What interventions are being tested in trial NCT06112340?
The interventions under investigation include: linsitinib (DRUG).
Who is sponsoring clinical trial NCT06112340?
This trial is sponsored by Sling Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06112340 being conducted?
This trial has 2 study locations across Florida, West Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Eye Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06112340's enrollment target sits among peer trials
75 14th of 27 higher than 14 of 27 other Eye Diseases trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Eye Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
SGLT2 Inhibitors in Geographic Atrophy
RECRUITING · Phase 2
-
A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Evaluate Efficacy, Safety, Tolerability and Exposure After a Repeat-dose of Sepofarsen (QR-110) in LCA10 (ILLUMINATE)
ACTIVE NOT RECRUITING · Phase 2
-
Efficacy and Safety of MCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE]
COMPLETED · Phase 2
-
Evaluation of the Safety and Effectiveness of Aceclidine/Brimonidine (LNZ101) and Aceclidine (LNZ100) in the Treatment of Presbyopia
COMPLETED · Phase 2
-
Anecortave Acetate for Treatment of Steroid Induced Intraocular Pressure (IOP) Elevation
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01535430 · 75 participants
Assessment of Eloquent Function in Brain Tumor Patients
- NCT01542879 · 75 participants · Phase 1
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
- NCT02232191 · 75 participants · Phase 2
Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients
- NCT02754544 · 75 participants · NA
Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI